OncoMatch/Clinical Trials/NCT05618821
Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer
Is NCT05618821 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Indocyanine Green Tracer for gastric cancer.
Treatment: Indocyanine Green Tracer — Patients with resectable remnant gastric cancer were selected as study subjects to investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in guiding laparoscopic lymph node dissection for remnant gastric cancer by comparing injection ICG group and non-injection ICG group.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Required: Stage N- (AJCC Seventh Edition)
Excluded: Stage DISTANT METASTASIS
cT1-4a, N-/+, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: neoadjuvant chemotherapy
History of previous neoadjuvant chemotherapy
Cannot have received: radiotherapy
History of previous neoadjuvant...radiotherapy
Lab requirements
Cardiac function
ASA class I to III; FEV1<50% of the predicted values excluded; history of unstable angina or myocardial infarction within past six months excluded
ASA (American Society of Anesthesiology) class I to III; FEV1<50% of the predicted values; History of unstable angina or myocardial infarction within the past six months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify